| GTO ID | GTC1339 |
| Trial ID | NCT01034410 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | nucleolin |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | AS1411 |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia |
| Year | 2009 |
| Country | Australia|New Zealand|China|United States |
| Company sponsor | Antisoma Research |
| Other ID(s) | AS1411-C-203 |
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||